Aquedeon Medical

Aquedeon Medical is a clinical-stage medical device developer focused on improving outcomes in aortic arch reconstruction surgery. The company's lead product, the Duett Vascular Graft System, aims to reduce circulatory arrest time by simplifying the connection of vascular grafts to native vessels, potentially lowering procedural risk and complexity. Having secured FDA Investigational Device Exemption (IDE) approval, the company is actively conducting a clinical trial (NCT06253143) to evaluate the system's safety and effectiveness. Aquedeon operates as a pre-revenue, private entity leveraging a surgeon-centric innovation philosophy to address a significant unmet need in cardiothoracic and vascular surgery.

The Duett Vascular Graft System, a specialized device designed to standardize and simplify the creation of anastomoses (surgical connections) between vascular grafts and native aortic arch vessels.

Competition includes established manual suturing techniques, which are the entrenched standard of care, and potential alternative anastomotic devices from larger cardiac surgery companies. The landscape is defined by high barriers to entry due to surgical complexity and regulatory hurdles, but also by a clear demand for technological improvement.